CAGX For Lab Research

CAGX – High-Purity Long-Acting Amylin Analogue Research Peptide | Peptides Lab UK

CAGX is a stable, lipidated, long-acting analogue of the pancreatic hormone amylin, designed to act on amylin and calcitonin receptors (AMY1R, AMY3R, and CTR), supplied by Peptides Lab UK in lyophilised format at >99% purity (HPLC verified) for in vitro and pre-clinical laboratory research use only.

Available to buy in the UK from Peptides Lab UK, CAGX is one of the most extensively studied long-acting amylin analogues in current metabolic research literature, with published data from Phase 1b, Phase 2, and Phase 3 clinical investigations. Each batch is independently quality-tested and distributed in a controlled lyophilised powder form, suitable for precise laboratory handling and storage.

What is CAGX?

CAGX (also referenced in research literature as compound 0833) is a synthetic, lipidated long-acting analogue of human amylin — a 37-amino acid peptide hormone co-secreted with insulin from pancreatic beta cells. Native amylin plays an important role in satiety signalling, acting via both the homeostatic and hedonic regions of the brain. However, it has a very short half-life and a high propensity to form amyloid fibrils, making it unsuitable for direct research or pharmacological application without structural modification.

CAGX was developed through a medicinal chemistry programme focused on overcoming these limitations. Its design incorporates the human amylin backbone with structural inspiration drawn from calcitonin, combined with a C20 fatty acid lipidation chain that enables reversible albumin binding — the same protraction mechanism used in semaglutide. The result is a compound with a confirmed half-life of approximately 159–195 hours in published pharmacokinetic studies, allowing for once-weekly dosing in clinical research settings.

As a non-selective agonist, CAGX targets both amylin receptors (AMY1R and AMY3R) — heterodimeric complexes formed between the calcitonin receptor (CTR) and receptor activity-modifying proteins RAMP1 and RAMP3 respectively — as well as the calcitonin receptor itself. This broad receptor engagement profile, combined with its extended pharmacokinetic profile, distinguishes CAGX from earlier amylin analogues such as pramlintide, which requires multiple daily injections due to its short duration of action.

CAGX – Key Research Facts

• Class: Long-acting amylin and calcitonin receptor agonist (non-selective)
• Primary receptors: AMY1R, AMY3R (RAMP1/3 + CTR heterodimers), and CTR
• Half-life: Approximately 159–195 hours (Phase 1b PK data)
• Lipidation: C20 fatty acid acylation side chain enabling reversible albumin binding
• Backbone: Based on human amylin sequence with calcitonin-inspired structural modifications
• Fibrillation: Structural mutations incorporated to reduce amyloid fibril formation risk
• Predecessor: Developed as a long-acting improvement over pramlintide (requires 3x daily dosing)
• Research designation: Also known as compound 0833 (Novo Nordisk internal reference)

What Does CAGX Do in Research?

In laboratory and pre-clinical research settings, CAGX is investigated for its ability to engage amylin and calcitonin receptor pathways and the downstream signalling effects this produces. When bound to AMY1R or AMY3R, CAGX activates intracellular signalling cascades — including adenylyl cyclase activation and cyclic AMP (cAMP) production — which have downstream relevance to appetite regulation, energy homeostasis, and metabolic parameters in experimental models.

Pre-clinical studies using diet-induced obese (DIO) rat and mouse models have demonstrated that CAGX produces dose-dependent reductions in food intake that are sustained for 48–60 hours following a single dose — a significant extension compared to native amylin or pramlintide. A published tool compound study (0174-0839) with 95% sequence homology to CAGX confirmed comparable effects on body weight reduction and fat mass in DIO models, and demonstrated additive effects when co-administered with semaglutide in rodent studies.

A 2025 receptor knockout (KO) study published in PMC confirmed that CAGX’s effects in vivo are primarily mediated through AMY1R and AMY3R (RAMP1/3-dependent pathways), with the absence of RAMP1 and RAMP3 significantly impairing the compound’s potency in DIO mouse models.

Key Research Areas for CAGX

• AMY1R and AMY3R receptor-binding and activation studies
• Amylin/calcitonin receptor pathway and downstream cAMP signalling research
• Structure-activity relationship (SAR) investigations within the amylin/calcitonin peptide family
• Pre-clinical food intake and energy homeostasis studies in DIO rodent models
• RAMP1/RAMP3 receptor activity-modifying protein interaction studies
• Comparative studies with pramlintide and other amylin analogues
• Dual-peptide synergy investigations alongside GLP-1 receptor agonists

What Do Studies Say About CAGX?

CAGX has a well-established and growing body of published research, spanning medicinal chemistry development, pre-clinical in vivo studies, receptor biology, and multiple phases of clinical investigation.

Medicinal Chemistry Development (Journal of Medicinal Chemistry, 2021)

The foundational published account of CAGX’s development was reported in the Journal of Medicinal Chemistry. Researchers documented the structure-activity relationship (SAR) programme that led to the selection of CAGX for clinical development. The study described the compound’s lipidation strategy, its mechanism of protracted action via reversible albumin binding, and its reduced fibrillation tendency compared to native amylin. Pre-clinical food intake data in rats showed a single dose of 3 nmol/kg producing a sustained reduction in food intake for up to 48–60 hours — far exceeding the duration achievable with pramlintide at comparable molar doses.

Reference: Lau J et al. (2021). Development of CAGX, a Long-Acting Amylin Analogue. Journal of Medicinal Chemistry. DOI: 10.1021/acs.jmedchem.1c00565. PubMed PMID: 34288673.

Phase 1b Pharmacokinetic Trial (The Lancet, 2021)

A randomised, controlled Phase 1b trial assessed the safety, tolerability, pharmacokinetics, and pharmacodynamics of CAGX across doses of 0.16–4.5 mg administered alongside Semaglutide 2.4 mg in 96 adults. The study confirmed a dose-proportional pharmacokinetic profile, with CAGX half-life established at 159–195 hours and median time to maximum concentration (tmax) of 24–72 hours. Exposure to Semaglutide was not affected by co-administration. Most adverse events were mild to moderate gastrointestinal in nature and were similar across treatment groups. The study provided the pharmacokinetic foundation for once-weekly dosing in subsequent trials.

Reference: Enebo LB et al. (2021). Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of CAGX with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. The Lancet. DOI: 10.1016/S0140-6736(21)00384-4. PubMed PMID: 33894838.

Phase 2 Dose-Finding Trial – Monotherapy (The Lancet, 2021)

A multicentre, randomised, double-blind, placebo- and active-controlled Phase 2 dose-finding trial evaluated once-weekly CAGX at doses of 0.3, 0.6, 1.2, 2.4, and 4.5 mg across 706 adults with overweight or obesity at 57 sites in 10 countries (including the UK). Over 26 weeks, all doses of CAGX produced greater weight reduction than placebo, with estimated treatment differences ranging from 3.0% to 7.8%. At the highest dose of 4.5 mg, CAGX also produced greater weight reduction than the active comparator liraglutide 3.0 mg (–10.8% vs –9.0%; estimated treatment difference 1.8%, p=0.03). The authors concluded this was the first study to establish a dose-response relationship for once-weekly CAGX as a monotherapy for weight management.

Reference: Enebo LB et al. (2021). Once-weekly CAGX for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. The Lancet. DOI: 10.1016/S0140-6736(21)01749-1. PubMed PMID: 34798060.

Receptor Mechanism Study – AMY1R & AMY3R (PMC, 2025)

A 2025 study published in PMC used RAMP1/RAMP3 knockout mouse models to investigate the specific receptor contributions to CAGX’s in vivo effects. Body weight loss was observed in wild-type mice treated with CAGX (–3.4 g, p<0.005), while the absence of RAMP1 and RAMP3 significantly impeded the compound’s potency. This confirmed that CAGX’s weight-relevant effects in pre-clinical models are primarily mediated through AMY1R and AMY3R rather than CTR alone — providing important mechanistic data for receptor-binding and pathway research using this compound.

Reference: PMC (2025). CAGX lowers bodyweight through brain amylin receptors 1 and 3. PMC Article PMC12270663.

Amylin Analogue Review (Expert Opinion, 2024)

A 2024 expert review published on PubMed examined the landscape of amylin analogues in obesity research, comparing pramlintide and CAGX. The review confirmed that CAGX had achieved weight reductions exceeding 10% of total body weight in early Phase 2 trials — a substantially greater reduction than those observed with pramlintide. The authors highlighted CAGX’s positioning as a promising component of combination approaches with other incretin-based compounds, and described the development of dual and triple co-agonist combinations as the most exciting future direction in this research field.

Reference: Expert Review (2024). Amylin analogs for the treatment of obesity without diabetes: present and future. PubMed PMID: 39317404.

CAGX UK – Specifications

Product Details

• Purity:>99% (HPLC verified)
• Form: Lyophilised powder
• Storage: Store dry at –20°C; protect from light
• Solubility: Bacteriostatic water, sterile water, or suitable laboratory solvents
• Distributed by: Peptides Lab UK
• Quality assurance: Rigorous batch-level analysis; certificate of analysis available on request

Research Applications

Suitable Laboratory Uses for CAGX

• AMY1R, AMY3R, and CTR receptor-binding and activation studies
• RAMP1 and RAMP3 receptor activity-modifying protein interaction research
• Structure–activity relationship (SAR) investigations in the amylin/calcitonin peptide superfamily
• Pre-clinical food intake and appetite signalling studies in vitro
• Downstream cAMP signalling cascade pathway research
• Comparative studies with pramlintide and other amylin analogues
• Dual-peptide combination pathway studies alongside GLP-1 receptor agonists
• Molecular analysis and controlled laboratory experiments

Why Buy CAGX in the UK from Peptides Lab UK?

Peptides Lab UK is a trusted UK-based supplier of research-grade peptides. All products are distributed in lyophilised format with batch-verified purity documentation. Whether you are looking to buy CAGX in the UK, sourcing a long-acting amylin analogue for laboratory research, or searching for a reliable UK peptides supplier with documented quality control, Peptides Lab UK provides consistent quality with rigorous third-party analysis on every batch.

Related Search Terms

Researchers searching for: buy CAGX UK, CAGX peptide UK, CAGX for sale UK, amylin analogue UK research, UK peptides research grade, Peptides UK lab supply, long-acting amylin UK, buy amylin analogue UK, CAGX in the UK, AMY1R AMY3R peptide UK, amylin receptor agonist UK research — Peptides Lab UK supplies this compound for qualified laboratory researchers within the United Kingdom.

Important Notice & Research Disclaimer

⚠️ This product is supplied by Peptides Lab UK strictly for laboratory research use only. CAGX as distributed by Peptides Lab UK is not intended for, and must not be used for, human consumption, medical treatment, self-administration, veterinary applications, or any use outside of a controlled laboratory environment. This compound is handled exclusively in controlled research settings for in vitro and pre-clinical studies.

Handling must only be performed by qualified and trained laboratory professionals in accordance with applicable regulations and institutional guidelines. Peptides Lab UK accepts no liability for any use of this compound outside of its intended laboratory research purpose.

References to clinical trials and published research throughout this description are provided for informational and research context only and do not constitute medical claims or endorsements of any therapeutic application of this product.